Adalimumab
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Non-infectious Intermediate Posterior- or Pan-uveitis
Conditions
Non-infectious Intermediate Posterior- or Pan-uveitis
Trial Timeline
Jul 7, 2022 → Jun 10, 2024
NCT ID
NCT05414201About Adalimumab
Adalimumab is a approved stage product being developed by AbbVie for Non-infectious Intermediate Posterior- or Pan-uveitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05414201. Target conditions include Non-infectious Intermediate Posterior- or Pan-uveitis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05414201 | Approved | Completed |
| NCT04183608 | Approved | Recruiting |
| NCT03311464 | Phase 3 | Completed |
| NCT03261102 | Pre-clinical | Active |
| NCT02897115 | Approved | Terminated |
| NCT02904902 | Phase 3 | Completed |
| NCT02668640 | Pre-clinical | Completed |
| NCT02750800 | Pre-clinical | Completed |
| NCT02739828 | Pre-clinical | Completed |
| NCT02634541 | Approved | UNKNOWN |
| NCT02632175 | Phase 3 | Completed |
| NCT02533375 | Phase 3 | Completed |
| NCT02499783 | Phase 3 | Completed |
| NCT02198651 | Approved | Completed |
| NCT02333383 | Pre-clinical | Completed |
| NCT02539849 | Pre-clinical | Completed |
| NCT02185014 | Phase 3 | Completed |
| NCT02148718 | Approved | Completed |
| NCT02065622 | Phase 3 | Completed |
| NCT02016482 | Phase 3 | Completed |
Competing Products
10 competing products in Non-infectious Intermediate Posterior- or Pan-uveitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LFG316 + Conventional Therapy | Novartis | Phase 2 | 52 |
| AIN457 + Placebo | Novartis | Phase 3 | 77 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 77 |
| AIN457 + AIN 457 + AIN457 | Novartis | Phase 2 | 52 |
| ESK-001 | Alumis | Phase 2 | 47 |
| Topical Prednisolone Acetate 1% | Ocular Therapeutix | Approved | 80 |
| FAI insert + Sham injection | EyePoint Pharmaceuticals | Phase 3 | 72 |
| FAI Insert administered using the Mk II inserter + FAI Insert administered using the Mk I inserter | EyePoint Pharmaceuticals | Phase 3 | 72 |
| ADX-102 Ophthalmic Solution (0.5%) + Vehicle of ADX-102 Ophthalmic Solution | Aldeyra Therapeutics | Phase 3 | 69 |
| NS2 + Prednisolone acetate ophthalmic suspension (1%) | Aldeyra Therapeutics | Phase 2 | 44 |